\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[english]{babel}



\usepackage{float}








\begin{document}

\title{A current perspective of Rosuvastatin usage and its complications:}



\author[1]{Govinda Khatri}%
\author[1]{Aneesh Rai}%
\affil[1]{Dow University of Health Sciences}%


\vspace{-1em}



  
  \date{May 08, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
Rosuvastatin is a lipid-lowering medication that is routinely used to
reduce blood cholesterol levels. It acts by inhibiting HMG-CoA
reductase, the rate-limiting enzyme in cholesterol production,
preventing de novo cholesterol synthesis and increasing the amount of
low-density lipoprotein (LDL) receptors on the liver surface, resulting
in lower blood LDL levels. Rosuvastatin has some adverse effects,
including moderate ones like headache, stomach discomfort, nausea, and
weakness, as well as major ones like muscle, liver, and renal issues
including severe muscular pain, decreased appetite, dark-colored urine,
and continuous nausea/vomiting. According to recent research,
rosuvastatin medication can produce renal tubular toxicity in persons
who have no prior history of kidney disease. Rosuvastatin has been
linked to myalgia, rhabdomyolysis, and elevated creatine phosphokinase
levels. If patients on rosuvastatin have muscular or renal difficulties,
they should seek emergency medical assistance. Nonetheless,
Rosuvastatin's lipid-lowering effects exceed the danger of adverse
effects. Strong adherence to these safety precautions can enhance
Rosuvastatin's safety profile and allow it to be given safely for
hypercholesterolemia.%
\end{abstract}%



\sloppy


\textbf{Hosted file}

\verb`Rosuvastatin.manusscript.docx`  available at \url{https://authorea.com/users/498976/articles/579659-a-current-perspective-of-rosuvastatin-usage-and-its-complications}

\selectlanguage{english}
\FloatBarrier
\end{document}

